体部伽玛刀联合化疗治疗中晚期非小细胞肺癌的临床疗效

摘要

目的:评价体部伽玛刀联合化疗治疗中晚期非小细胞肺癌(NSCLC)的临床疗效.方法:观察中晚期NSCLC患者186例,体部伽玛刀治疗单次外周剂量4～5Gy,治疗次数8～12次,总剂量40～50Gy;放疗结束后2周实施化疗,使用吉西他滨(Gemcitabine)1000mg/m2,第1、8天,顺铂(DDP)30mg/m2,第1-3天,每21天为1周期,至少完成2周期化疗,伽玛刀治疗结束后3月评价疗效.结果:186例惠者均完成治疗,近期疗效评价总有效率(CR+PR)88.17%,随访36与月,1年生存率61.29%,2年生存率42.47%,3年生存率33.87%.随访期内未见严重放射性并发症.结论:采用体部伽玛刀联合化疗治疗中晚期肺癌,具有较高的近期疗效,毒副反应较轻,患者可以耐受%Objective:To evaluate the effects ofboby-gamma knife radiotherapy followed by chemotherapy for local advanced non-small-cell lung cancer. Methods: 186 patients with local advanced non-small-cell lungcancer received boby-gamma knife radiotherapy followed by chemotherapy Irradiation dose was 40～50Gy,4-SGy/fraction, 8～12 fractions. Chemotherapy consisted of GEM 1000mg/m2,dl, 8; DDP 30mg/m2, d1～3,21 days per cycle.At least 2 cycles were delivered. Results: 186 patients were allotted,The total eficacy rate was 88.17％. In the follow-up of 36 months, the survival rates at 1,2,3 year were 61.29％, 42.47％ and33.87％, respectively. Conclusion: Body-knife combined with concurrent chemotherapy is a feasible, safe,and efective method and could be well tolerated in most patients. It is a good treatment for patients with advanced lung cancer and deserves further investigation.